Alzinova AB (publ) (ALZ.ST)
SEK 3.5
(0.0%)
SEK 3.5
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 123.18 Million SEK | 10.36% |
| 2022 | 111.62 Million SEK | 21.74% |
| 2021 | 91.69 Million SEK | -9.05% |
| 2020 | 100.81 Million SEK | 58.69% |
| 2019 | 63.53 Million SEK | -3.87% |
| 2018 | 66.08 Million SEK | 108.34% |
| 2017 | 31.72 Million SEK | -4.78% |
| 2016 | 33.31 Million SEK | 50.06% |
| 2015 | 22.19 Million SEK | 936.44% |
| 2014 | 2.14 Million SEK | 47.54% |
| 2013 | 1.45 Million SEK | 29.94% |
| 2012 | 1.11 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 117.06 Million SEK | -4.97% |
| 2024 Q2 | 112.39 Million SEK | -3.99% |
| 2023 Q2 | 126.73 Million SEK | 18.37% |
| 2023 Q3 | 126.32 Million SEK | -0.32% |
| 2023 Q4 | 123.18 Million SEK | -2.48% |
| 2023 FY | 123.18 Million SEK | 10.36% |
| 2023 Q1 | 107.06 Million SEK | -4.08% |
| 2022 FY | 111.62 Million SEK | 21.74% |
| 2022 Q4 | 111.62 Million SEK | -2.9% |
| 2022 Q1 | 97.16 Million SEK | 5.97% |
| 2022 Q2 | 117.21 Million SEK | 20.63% |
| 2022 Q3 | 114.95 Million SEK | -1.92% |
| 2021 FY | 91.69 Million SEK | -9.05% |
| 2021 Q3 | 94.11 Million SEK | -4.58% |
| 2021 Q2 | 98.62 Million SEK | -2.36% |
| 2021 Q4 | 91.69 Million SEK | -2.58% |
| 2021 Q1 | 101.01 Million SEK | 0.2% |
| 2020 Q3 | 58.5 Million SEK | -4.08% |
| 2020 Q4 | 100.81 Million SEK | 72.31% |
| 2020 FY | 100.81 Million SEK | 58.69% |
| 2020 Q1 | 62.46 Million SEK | -1.68% |
| 2020 Q2 | 60.99 Million SEK | -2.36% |
| 2019 Q3 | 64.33 Million SEK | -1.78% |
| 2019 Q1 | 65.58 Million SEK | -0.76% |
| 2019 FY | 63.53 Million SEK | -3.87% |
| 2019 Q4 | 63.53 Million SEK | -1.25% |
| 2019 Q2 | 65.49 Million SEK | -0.14% |
| 2018 Q3 | 31.31 Million SEK | 1.69% |
| 2018 FY | 66.08 Million SEK | 108.34% |
| 2018 Q2 | 30.79 Million SEK | -0.23% |
| 2018 Q1 | 30.86 Million SEK | -2.69% |
| 2018 Q4 | 66.08 Million SEK | 111.03% |
| 2017 Q1 | 32.6 Million SEK | -2.12% |
| 2017 FY | 31.72 Million SEK | -4.78% |
| 2017 Q4 | 31.72 Million SEK | -2.86% |
| 2017 Q3 | 32.65 Million SEK | -0.32% |
| 2017 Q2 | 32.75 Million SEK | 0.47% |
| 2016 FY | 33.31 Million SEK | 50.06% |
| 2016 Q3 | 20.78 Million SEK | -1.33% |
| 2016 Q2 | 21.06 Million SEK | -2.76% |
| 2016 Q1 | 21.66 Million SEK | -2.4% |
| 2016 Q4 | 33.31 Million SEK | 60.24% |
| 2015 Q1 | - SEK | -100.0% |
| 2015 FY | 22.19 Million SEK | 936.44% |
| 2015 Q4 | 22.19 Million SEK | 0.0% |
| 2014 FY | 2.14 Million SEK | 47.54% |
| 2014 Q4 | 2.14 Million SEK | 0.0% |
| 2013 FY | 1.45 Million SEK | 29.94% |
| 2012 FY | 1.11 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 118.45 Million SEK | -4.001% |
| Ziccum AB (publ) | 14.97 Million SEK | -722.796% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -514.685% |
| BioArctic AB (publ) | 1.18 Billion SEK | 89.614% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -97.491% |
| Mendus AB (publ) | 755.95 Million SEK | 83.704% |
| Genovis AB (publ.) | 288.85 Million SEK | 57.353% |
| Intervacc AB (publ) | 259.61 Million SEK | 52.549% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -193.594% |
| Active Biotech AB (publ) | 44 Million SEK | -179.975% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 55.806% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -98.206% |
| Aptahem AB (publ) | 63.02 Million SEK | -95.461% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 75.176% |
| Kancera AB (publ) | 65.64 Million SEK | -87.665% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 64.937% |
| Fluicell AB (publ) | 9.34 Million SEK | -1218.94% |
| Saniona AB (publ) | 64.14 Million SEK | -92.054% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -266.612% |
| Biovica International AB (publ) | 131.4 Million SEK | 6.255% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -132.498% |
| AcouSort AB (publ) | 34.51 Million SEK | -256.935% |
| Xintela AB (publ) | 18.39 Million SEK | -569.687% |
| Abliva AB (publ) | 87.49 Million SEK | -40.789% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 83.795% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 90.211% |
| OncoZenge AB (publ) | 20.34 Million SEK | -505.649% |
| Amniotics AB (publ) | 26.08 Million SEK | -372.242% |
| 2cureX AB (publ) | 16.62 Million SEK | -640.986% |
| CombiGene AB (publ) | 120.61 Million SEK | -2.137% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -1927.135% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 93.518% |
| Camurus AB (publ) | 1.9 Billion SEK | 93.543% |
| Corline Biomedical AB | 100.1 Million SEK | -23.06% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 30.449% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 12.381% |
| I-Tech AB | 152.44 Million SEK | 19.19% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 87.899% |
| Cyxone AB (publ) | 43.65 Million SEK | -182.188% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -56.546% |
| Biosergen AB | 7.2 Million SEK | -1610.721% |
| Cantargia AB (publ) | 223.71 Million SEK | 44.934% |
| NextCell Pharma AB | 81.28 Million SEK | -51.546% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 83.902% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -308.275% |
| Nanologica AB (publ) | 77.42 Million SEK | -59.099% |
| SynAct Pharma AB | 228.01 Million SEK | 45.974% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -360.296% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -467.616% |
| LIDDS AB (publ) | 17.65 Million SEK | -597.757% |
| Lipum AB (publ) | 12.11 Million SEK | -917.25% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 91.202% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 48.322% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -1356.996% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | -44.542% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -728.496% |
| Simris Alg AB (publ) | 174.55 Million SEK | 29.426% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 43.241% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 81.15% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | -41.479% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -332.121% |